Metotrexato Accord

Methotrexate, the active ingredient in Metotrexato Accord, is a folate antagonist presented as a sterile solution for intraarterial, intramuscular, intrathecal use. It is employed to manage autoimmune disorders and several malignant diseases in adult and pediatric patients.

GNH USA supplies Metotrexato Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate acts on rapidly dividing cells and immune pathways, making it useful across several disease families. - Rheumatoid arthritis: reduces inflammation and slows joint damage in adult patients. - Psoriasis: limits skin cell proliferation, improving plaque severity. - Acute lymphoblastic leukemia: interferes with leukemic cell replication, supporting remission. - Non‑Hodgkin lymphoma: hampers malignant B‑cell growth as part of combination regimens. - Gestational trophoblastic disease: induces regression of trophoblastic tissue after curettage.

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Oral mucosal ulceration. - Mild elevation of liver enzymes. - Transient low blood cell counts. - Mild alopecia.

Serious or Rare Side Effects: - Severe hepatotoxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Life‑threatening infection due to bone‑marrow suppression. - Acute renal failure. - Severe pancytopenia. - Anaphylactoid reactions on rapid infusion.

Before initiating therapy, clinicians should assess baseline organ function and counsel patients on risk mitigation. - Monitor blood counts: perform regular CBC to detect myelosuppression. - Assess liver function: check transaminases and bilirubin periodically. - Evaluate renal function: adjust dosing if creatinine clearance is reduced. - Contraindicated in pregnancy: ensure effective contraception for women of child‑bearing potential. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Methotrexate interacts with several drugs that can amplify toxicity or reduce efficacy.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate serum levels and risk of nephrotoxicity. - Trimethoprim‑sulfamethoxazole: potentiates myelosuppression. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression. - Phenytoin and other enzyme inducers: may lower methotrexate concentrations. - Folic acid supplementation: can reduce efficacy if high doses are used.